Company registration number 01529851 (England and Wales)
NO. 7 CONTACT LENS LABORATORY LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025
NO. 7 CONTACT LENS LABORATORY LIMITED
COMPANY INFORMATION
Directors
B G Andrews
A Ricupati
G E Ley
Company number
01529851
Registered office
Delta Park Concorde Way
Segensworth North
Fareham
England
PO15 5RL
Auditor
Azets Audit Services
5th Floor
Ashford Commercial Quarter
1 Dover Place
Ashford
Kent
United Kingdom
TN23 1FB
NO. 7 CONTACT LENS LABORATORY LIMITED
CONTENTS
Page
Directors' report
1 - 2
Directors' responsibilities statement
3
Independent auditor's report
4 - 6
Statement of income and retained earnings
7
Balance sheet
8
Notes to the financial statements
9 - 19
NO. 7 CONTACT LENS LABORATORY LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 OCTOBER 2025
The directors present their annual report and financial statements for the year ended 31 October 2025.
Principal activities
The principal activity of the company continued to be that of the manufacture and sale of contact lenses and related products.
Results and dividends
The results for the year are set out on page 7.
No ordinary dividends were paid. The directors do not recommend payment of a final dividend.
Directors
The directors who held office during the year and up to the date of signature of the financial statements were as follows:
B G Andrews
A Ricupati
G E Ley
Going concern
The financial statements have been prepared on a going concern basis which the directors consider to be appropriate for the following reasons.
The company prepares a cash flow forecast which shows that the company will generate positive cash and be able to meet its liabilities as they fall due for the next 12 months.
The directors have considered the cash flow forecasts in performing a going concern assessment for the company which covers a period of at least 12 months from the date of approval of these financial statements. In what the Directors deem to be an unlikely event that additional funding is required the company has the continued financial support from its ultimate parent company, The Cooper Companies Inc.
The Cooper Companies has indicated its intention to make available funding to cover intercompany and other external liabilities for the period covered by the forecasts, this includes agreeing that intercompany creditor balances will not be called in within 12 months from the date of the approval of the financial statements, unless the company is in a position to be able to repay this balance. This financial support will continue in place for at least a period covering 12 months from the date of the approval of these financial statements.
As with any company placing reliance on other group entities for financial support, the directors acknowledge that there can be no certainty that this support will continue although, at the date of approval of these financial statements, they have no reason to believe that it will not do so.
Consequently, the directors are confident that the company will have sufficient funds to continue to meet its liabilities as they fall due for at least 12 months from the date of approval of the financial statements and therefore have prepared the financial statements on a going concern basis.
Statement of disclosure to auditor
So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the company’s auditor is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the company’s auditor is aware of that information.
- 1 -
Strategic report exemptionfalse
Exemption has been taken from preparing a Strategic Report under S414B(b) of The Companies Act 2006 (Strategic Report and Directors' Report) Regulations 2013 on the grounds that the company would qualify as a small company were it not a member of an ineligible group.
NO. 7 CONTACT LENS LABORATORY LIMITED
DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
On behalf of the board
G E Ley
Director
27 July 2026
- 2 -
NO. 7 CONTACT LENS LABORATORY LIMITED
DIRECTORS' RESPONSIBILITIES STATEMENT
FOR THE YEAR ENDED 31 OCTOBER 2025
- 3 -
The directors are responsible for preparing the annual report and the financial statements in accordance with applicable law and regulations.
Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period.
In preparing these financial statements, the directors are required to:
select suitable accounting policies and then apply them consistently;
make judgements and accounting estimates that are reasonable and prudent;
state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.
The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
NO. 7 CONTACT LENS LABORATORY LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF NO. 7 CONTACT LENS LABORATORY LIMITED
- 4 -
Opinion
We have audited the financial statements of No. 7 Contact Lens Laboratory Limited (the 'company') for the year ended 31 October 2025 which comprise the statement of income and retained earnings, the balance sheet and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).
In our opinion the financial statements:
give a true and fair view of the state of the company's affairs as at 31 October 2025 and of its profit for the year then ended;
have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
have been prepared in accordance with the requirements of the Companies Act 2006.
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.
Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.
Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.
The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.
We have nothing to report in this regard.
Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of our audittrue:
the information given in the directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
the directors' report has been prepared in accordance with applicable legal requirements.
NO. 7 CONTACT LENS LABORATORY LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF NO. 7 CONTACT LENS LABORATORY LIMITED (CONTINUED)
Matters on which we are required to report by exception
In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report. We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:
adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
the financial statements are not in agreement with the accounting records and returns; or
certain disclosures of directors' remuneration specified by law are not made; or
we have not received all the information and explanations we require for our audit; or
the directors were not entitled to take advantage of the small companies exemption from the requirement to prepare a strategic report.
Responsibilities of directors
- 5 -
As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.
Auditor's responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
A further description of our responsibilities is available on the Financial Reporting Council’s website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.
NO. 7 CONTACT LENS LABORATORY LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF NO. 7 CONTACT LENS LABORATORY LIMITED (CONTINUED)
Extent to which the audit was considered capable of detecting irregularities, including fraud
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above and on the Financial Reporting Council’s website, to detect material misstatements in respect of irregularities, including fraud.
We obtain and update our understanding of the entity, its activities, its control environment, and likely future developments, including in relation to the legal and regulatory framework applicable and how the entity is complying with that framework. Based on this understanding, we identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. This includes consideration of the risk of acts by the entity that were contrary to applicable laws and regulations, including fraud.
In response to the risk of irregularities and non-compliance with laws and regulations, including fraud, we designed procedures which included:
Enquiry of management and those charged with governance around actual and potential litigation and claims as well as actual, suspected and alleged fraud;
Assessing the extent of compliance with the laws and regulations considered to have a direct material effect on the financial statements or the operations of the company through enquiry and inspection;
Reviewing financial statement disclosures and testing to supporting documentation to assess compliance with applicable laws and regulations;
Performing audit work over the risk of management bias and override of controls, including testing of journal entries and other adjustments for appropriateness, evaluating the business rationale of significant transactions outside the normal course of business and reviewing accounting estimates for indicators of potential bias.
Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.
Christiaan de Lange (Senior Statutory Auditor)
For and on behalf of Azets Audit Services, Statutory Auditor
Chartered Accountants
5th Floor
Ashford Commercial Quarter
1 Dover Place
Ashford
Kent
TN23 1FB
29 July 2026
- 6 -
NO. 7 CONTACT LENS LABORATORY LIMITED
STATEMENT OF INCOME AND RETAINED EARNINGS
FOR THE YEAR ENDED 31 OCTOBER 2025
2025
2024
Notes
£
£
Turnover
4,893,246
5,205,743
Cost of sales
(1,999,488)
(2,580,308)
Gross profit
2,893,758
2,625,435
Administrative expenses
(2,297,143)
(1,979,527)
Operating profit
4
596,615
645,908
Interest receivable and similar income
6
12,002
545
Interest payable and similar expenses
7
(27,126)
Profit before taxation
608,617
619,327
Tax on profit
8
(216,874)
(70,260)
Profit for the financial year
391,743
549,067
Retained earnings brought forward
2,805,938
2,256,871
Retained earnings carried forward
3,197,681
2,805,938
The profit and loss account has been prepared on the basis that all operations are continuing operations.
- 7 -
NO. 7 CONTACT LENS LABORATORY LIMITED
BALANCE SHEET
AS AT 31 OCTOBER 2025
31 October 2025
Year
Year
ended
ended
31 October
31 October
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
10
2,581,505
2,126,008
Current assets
Stocks
11
122,782
146,949
Debtors
12
818,714
766,190
Cash at bank and in hand
845,973
706,194
1,787,469
1,619,333
Creditors: amounts falling due within one year
13
(751,699)
(523,288)
Net current assets
1,035,770
1,096,045
Total assets less current liabilities
3,617,275
3,222,053
Provisions for liabilities
Deferred tax liability
14
419,424
415,945
(419,424)
(415,945)
Net assets
3,197,851
2,806,108
Capital and reserves
Called up share capital
16
120
120
Capital redemption reserve
50
50
Profit and loss reserves
3,197,681
2,805,938
Total equity
3,197,851
2,806,108
The financial statements were approved by the board of directors and authorised for issue on 27 July 2026 and are signed on its behalf by:
G E Ley
Director
Company Registration No. 01529851
- 8 -
NO. 7 CONTACT LENS LABORATORY LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025
1
Accounting policies
Company information
No. 7 Contact Lens Laboratory Limited is a private company limited by shares incorporated in England and Wales. The registered office is Delta Park Concorde Way, Segensworth North, Fareham, England, PO15 5RL. The principal place of business is Unit 3 Highfields Business Park, Sidney Little Road, Hastings, East Sussex, TN38 9UB.
1.1
Accounting convention
These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.
This company is a qualifying entity for the purposes of FRS 102, being a member of a group where the parent of that group prepares publicly available consolidated financial statements, including this company, which are intended to give a true and fair view of the assets, liabilities, financial position and profit or loss of the group. The company has therefore taken advantage of exemptions from the following disclosure requirements:
Section 7 ‘Statement of Cash Flows’: Presentation of a statement of cash flow and related notes and disclosures;true
Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instrument Issuestrue: Interest income/expense and net gains/losses for financial instruments not measured at fair value; basis of determining fair values; details of collateral, loan defaults or breaches, details of hedges, hedging fair value changes recognised in profit or loss and in other comprehensive income;
Section 33 ‘Related Party Disclosures’true: Compensation for key management personnel.
- 9 -
Exemption has been taken from preparing a Strategic Report under S414B(b) of The Companies Act 2006 (Strategic Report and Directors' Report) Regulations 2013 on the grounds that the company would qualify as a small company were it not a member of an ineligible group.
NO. 7 CONTACT LENS LABORATORY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
1
Accounting policies
(Continued)
1.2
Going concern
The financial statements have been prepared on a going concern basis which the directors consider to be appropriate for the following reasons.true
The company prepares a cash flow forecast which shows that the company will generate positive cash and be able to meet its liabilities as they fall due for the next 12 months.
The directors have considered the cash flow forecasts in performing a going concern assessment for the company which covers a period of at least 12 months from the date of approval of these financial statements. In what the Directors deem to be an unlikely event that additional funding is required the company has the continued financial support from its ultimate parent company, The Cooper Companies Inc.
The Cooper Companies has indicated its intention to make available funding to cover intercompany and other external liabilities for the period covered by the forecasts, this includes agreeing that intercompany creditor balances will not be called in within 12 months from the date of the approval of the financial statements, unless the company is in a position to be able to repay this balance. This financial support will continue in place for at least a period covering 12 months from the date of the approval of these financial statements.
As with any company placing reliance on other group entities for financial support, the directors acknowledge that there can be no certainty that this support will continue although, at the date of approval of these financial statements, they have no reason to believe that it will not do so.
Consequently, the directors are confident that the company will have sufficient funds to continue to meet its liabilities as they fall due for at least 12 months from the date of approval of the financial statements and therefore have prepared the financial statements on a going concern basis.
1.3
Turnover
Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.
1.4
Intangible fixed assets - goodwill
Goodwill represents the excess of the cost of acquisition of unincorporated businesses over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a useful life of 5 years.
1.5
Intangible fixed assets other than goodwill
- 10 -
Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.
Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Patents
20% straight line
Patents are valued at cost less accumulated amortisation. Amortisation is calculated to write off the cost in equal annual instalments over their estimated useful lives.
1.6
Tangible fixed assets
Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.
NO. 7 CONTACT LENS LABORATORY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
1
Accounting policies
(Continued)
Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Long leasehold
30 year straight line basis
Short leasehold
Over the period of the lease
Plant and machinery
5, 7, 10 & 15 year straight line basis
Fixtures, fittings and equipment
20% on cost
- 11 -
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.
1.7
Impairment of fixed assets
At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If there is an indication of possible impairment, the recoverable amount of any affected asset is estimated and compared with its carrying amount. If the estimated recoverable amount is lower, the carrying amount is reduced to its estimated recoverable amount, and an impairment loss is recognised immediately in profit or loss.
If an impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of its recoverable amount, but not in excess of the amount that would have been determined had no impairment loss been recognised for the asset in prior years. A reversal of impairment is recognised immediately in profit or loss.
1.8
Stocks
Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.
Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.
At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.
1.9
Cash and cash equivalents
Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.
1.10
Financial instruments
The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.
Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.
Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
NO. 7 CONTACT LENS LABORATORY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
1
Accounting policies
(Continued)
Basic financial assets
- 12 -
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.
Other financial assets
Other financial assets, including investments in equity instruments which are not subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the transaction price. Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are measured at cost less impairment.
Impairment of financial assets
Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.
Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.
If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.
Derecognition of financial assets
Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the company transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.
Classification of financial liabilities
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.
Basic financial liabilities
Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.
Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.
NO. 7 CONTACT LENS LABORATORY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
1
Accounting policies
(Continued)
Other financial liabilities
- 13 -
Derivatives, including interest rate swaps and forward foreign exchange contracts, are not basic financial instruments. Derivatives are initially recognised at fair value on the date a derivative contract is entered into and are subsequently re-measured at their fair value. Changes in the fair value of derivatives are recognised in profit or loss in finance costs or finance income as appropriate, unless hedge accounting is applied and the hedge is a cash flow hedge.
Debt instruments that do not meet the conditions in FRS 102 paragraph 11.9 are subsequently measured at fair value through profit or loss. Debt instruments may be designated as being measured at fair value through profit or loss to eliminate or reduce an accounting mismatch or if the instruments are measured and their performance evaluated on a fair value basis in accordance with a documented risk management or investment strategy.
Derecognition of financial liabilities
Financial liabilities are derecognised when the company’s contractual obligations expire or are discharged or cancelled.
1.11
Equity instruments
Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.
1.12
Taxation
The tax expense represents the sum of the tax currently payable and deferred tax.
Current tax
The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.
Deferred tax
Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.
The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.
NO. 7 CONTACT LENS LABORATORY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
1
Accounting policies
(Continued)
1.13
Employee benefits
The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.
The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.
Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.
1.14
Retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to the profit and loss account in the period to which they relate.
1.15
Leases
Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.
1.16
Foreign exchange
Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.
2
Judgements and key sources of estimation uncertainty
In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.
3
Auditor's remuneration
2025
2024
Fees payable to the company's auditor and associates:
£
£
For audit services
Audit of the financial statements of the company
31,000
30,000
- 14 -
NO. 7 CONTACT LENS LABORATORY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
4
Operating profit
2025
2024
Operating profit for the year is stated after charging:
£
£
Exchange losses
10,032
252
Fees payable to the company's auditor for the audit of the company's financial statements
31,000
30,000
Depreciation of owned tangible fixed assets
215,363
188,787
Loss on disposal of tangible fixed assets
30,581
947
Operating lease charges
84,026
78,779
5
Employees
The average monthly number of persons (including directors) employed by the company during the year was:
2025
2024
Number
Number
37
46
Their aggregate remuneration comprised:
2025
2024
£
£
Wages and salaries
1,516,275
1,674,477
Social security costs
119,545
109,541
Pension costs
38,926
41,444
1,674,746
1,825,462
6
Interest receivable and similar income
2025
2024
£
£
Interest income
Other interest income
12,002
545
7
Interest payable and similar expenses
2025
2024
£
£
Interest on bank overdrafts and loans
-
192
Interest payable to group undertakings
26,934
27,126
- 15 -
NO. 7 CONTACT LENS LABORATORY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
8
Taxation
2025
2024
£
£
Current tax
UK corporation tax on profits for the current period
143,264
Adjustments in respect of prior periods
70,131
(1,329)
Total current tax
213,395
(1,329)
Deferred tax
Origination and reversal of timing differences
3,479
71,589
Total tax charge
216,874
70,260
The actual charge for the year can be reconciled to the expected charge for the year based on the profit or loss and the standard rate of tax as follows:
2025
2024
£
£
Profit before taxation
608,617
619,327
Expected tax charge based on the standard rate of corporation tax in the UK of 25.00% (2024: 25.00%)
152,154
154,832
Tax effect of expenses that are not deductible in determining taxable profit
8,002
Group relief
(62,785)
Other permanent differences
33
(28,460)
Under/(over) provided in prior years
64,687
(1,329)
Taxation charge for the year
216,874
70,260
Impact of BEPS - Pillar Two on the company
The company is a member of The Cooper Companies Group which is expected to be a multinational enterprise within the scope of Pillar Two from 1 November 2024.
The Cooper Companies Group has carried out a high level assessment of the impact of Pillar Two and it is expected that there will not be a material impact on the group in the short term.
- 16 -
NO. 7 CONTACT LENS LABORATORY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
9
Intangible fixed assets
Goodwill
Patents
Total
£
£
£
Cost
At 1 November 2024
60,000
106,863
166,863
Disposals
(60,000)
(75,000)
(135,000)
At 31 October 2025
31,863
31,863
Amortisation and impairment
At 1 November 2024
60,000
106,863
166,863
Disposals
(60,000)
(75,000)
(135,000)
At 31 October 2025
31,863
31,863
Carrying amount
At 31 October 2025
At 31 October 2024
10
Tangible fixed assets
Long leasehold
Short leasehold
Plant and machinery
Fixtures, fittings and equipment
Total
£
£
£
£
£
Cost
At 1 November 2024
498,218
50,764
2,934,958
348,740
3,832,680
Additions
92,301
619,549
711,850
Disposals
(50,764)
(951,279)
(275,301)
(1,277,344)
At 31 October 2025
590,519
2,603,228
73,439
3,267,186
Depreciation and impairment
At 1 November 2024
75,085
50,764
1,252,676
328,147
1,706,672
Depreciation charged in the year
16,059
184,118
15,186
215,363
Eliminated in respect of disposals
(50,764)
(910,289)
(275,301)
(1,236,354)
At 31 October 2025
91,144
526,505
68,032
685,681
Carrying amount
At 31 October 2025
499,375
2,076,723
5,407
2,581,505
At 31 October 2024
423,133
1,682,282
20,593
2,126,008
11
Stocks
2025
2024
£
£
Finished goods and goods for resale
122,782
146,949
- 17 -
NO. 7 CONTACT LENS LABORATORY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
12
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
714,501
696,031
Amounts owed by group undertakings
8,762
Other debtors
2,653
Prepayments and accrued income
95,451
67,506
818,714
766,190
13
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
119,724
104,908
Amounts owed to group undertakings
336,325
100,974
Taxation and social security
104,517
137,418
Other creditors
11,814
5,138
Accruals and deferred income
179,319
174,850
751,699
523,288
14
Deferred taxation
The following are the major deferred tax liabilities and assets recognised by the company and movements thereon:
Liabilities
Liabilities
2025
2024
Balances:
£
£
Accelerated capital allowances
420,208
416,698
Retirement benefit obligations
(784)
(753)
419,424
415,945
2025
Movements in the year:
£
Liability at 1 November 2024
415,945
Charge to profit or loss
3,479
Liability at 31 October 2025
419,424
The deferred tax liability set out above relates to accelerated capital allowances and retirement benefit obligations that are expected to mature in the foreseeable future.
- 18 -
NO. 7 CONTACT LENS LABORATORY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
15
Retirement benefit schemes
2025
2024
Defined contribution schemes
£
£
Charge to profit or loss in respect of defined contribution schemes
38,926
41,444
The company operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the company in an independently administered fund.
16
Share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
120
120
120
120
17
Operating lease commitments
As lessee
At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:
2025
2024
£
£
Within 1 year
50,316
49,204
Years 2-5
81,525
109,550
After 5 years
1,244,404
1,259,635
1,376,245
1,418,389
18
Related party transactions
The company has taken advantage of the exemption available in FRS 102 whereby it has not disclosed transactions entered into between two or more members of a group, where the subsidiary which is party to the transactions is wholly owned by such a member.true
19
Ultimate controlling party
Throughout the reporting period the immediate parent company was CooperVision (UK) Holdings Limited, incorporated in the United Kingdom. As of 31 October 2025 shares were transferred to CooperVision International Limited, incorporated in the United Kingdom . The ultimate parent is The Cooper Companies Inc., incorporated in the United States of America. The most senior parent entity producing publicly available financial statements is The Cooper Companies Inc.. These financial statements are available upon request from 6101 Bollinger Canyon Rd, Suite 500, San Ramon, CA 94583, USA.
- 19 -
2025-10-312024-11-01falsetruefalseCCH SoftwareCCH Accounts Production 2026.100B G AndrewsA RicupatiG E Ley015298512024-11-012025-10-3101529851bus:Director12024-11-012025-10-3101529851bus:Director22024-11-012025-10-3101529851bus:Director32024-11-012025-10-3101529851bus:RegisteredOffice2024-11-012025-10-31015298512025-10-31015298512023-11-012024-10-3101529851core:RetainedEarningsAccumulatedLosses2024-10-3101529851core:RetainedEarningsAccumulatedLosses2023-10-3101529851core:RetainedEarningsAccumulatedLosses2025-10-3101529851core:RetainedEarningsAccumulatedLosses2024-10-3101529851core:ShareCapital2025-10-3101529851core:ShareCapital2024-10-3101529851core:CapitalRedemptionReserve2025-10-3101529851core:CapitalRedemptionReserve2024-10-31015298512024-10-3101529851core:ShareCapitalOrdinaryShareClass12025-10-3101529851core:ShareCapitalOrdinaryShareClass12024-10-3101529851core:LandBuildingscore:OwnedOrFreeholdAssets2025-10-3101529851core:ShortLeaseholdAssets2025-10-3101529851core:PlantMachinery2025-10-3101529851core:FurnitureFittings2025-10-3101529851core:LandBuildingscore:OwnedOrFreeholdAssets2024-10-3101529851core:LandBuildings2024-10-3101529851core:PlantMachinery2024-10-3101529851core:FurnitureFittings2024-10-3101529851core:CurrentFinancialInstrumentscore:WithinOneYear2025-10-3101529851core:CurrentFinancialInstrumentscore:WithinOneYear2024-10-3101529851core:CurrentFinancialInstruments2025-10-3101529851core:CurrentFinancialInstruments2024-10-3101529851core:Goodwill2024-11-012025-10-3101529851core:IntangibleAssetsOtherThanGoodwill2024-11-012025-10-3101529851core:PatentsTrademarksLicencesConcessionsSimilar2024-11-012025-10-3101529851core:LandBuildingscore:OwnedOrFreeholdAssets2024-11-012025-10-3101529851core:LandBuildingscore:LongLeaseholdAssets2024-11-012025-10-3101529851core:PlantMachinery2024-11-012025-10-3101529851core:FurnitureFittings2024-11-012025-10-3101529851core:UKTax2024-11-012025-10-3101529851core:UKTax2023-11-012024-10-310152985112024-11-012025-10-310152985112023-11-012024-10-310152985122024-11-012025-10-310152985122023-11-012024-10-3101529851core:Goodwill2024-10-3101529851core:PatentsTrademarksLicencesConcessionsSimilar2024-10-31015298512024-10-3101529851core:Goodwill2025-10-3101529851core:PatentsTrademarksLicencesConcessionsSimilar2025-10-3101529851core:Goodwill2024-10-3101529851core:PatentsTrademarksLicencesConcessionsSimilar2024-10-3101529851core:LandBuildingscore:OwnedOrFreeholdAssets2024-10-3101529851core:LandBuildingscore:LeasedAssetsHeldAsLessee2024-10-3101529851core:PlantMachinery2024-10-3101529851core:FurnitureFittings2024-10-3101529851core:LandBuildingscore:LeasedAssetsHeldAsLessee2025-10-3101529851core:LandBuildingscore:LeasedAssetsHeldAsLessee2024-11-012025-10-3101529851core:AcceleratedTaxDepreciationDeferredTax2025-10-3101529851core:AcceleratedTaxDepreciationDeferredTax2024-10-3101529851core:RetirementBenefitObligationsDeferredTax2025-10-3101529851core:RetirementBenefitObligationsDeferredTax2024-10-3101529851dpl:Item12024-11-012025-10-3101529851dpl:Item12023-11-012024-10-3101529851bus:OrdinaryShareClass12024-11-012025-10-3101529851bus:OrdinaryShareClass12025-10-3101529851bus:OrdinaryShareClass12024-10-3101529851core:WithinOneYear2025-10-3101529851core:WithinOneYear2024-10-3101529851core:BetweenTwoFiveYears2025-10-3101529851core:BetweenTwoFiveYears2024-10-3101529851core:MoreThanFiveYears2025-10-3101529851core:MoreThanFiveYears2024-10-3101529851bus:PrivateLimitedCompanyLtd2024-11-012025-10-3101529851bus:FRS1022024-11-012025-10-3101529851bus:Audited2024-11-012025-10-3101529851bus:FullAccounts2024-11-012025-10-31xbrli:purexbrli:sharesiso4217:GBP